U.S. tariff impact on pharma exports
Potential U.S. tariffs could affect pricing and margins; management acknowledged uncertainty and said they will evaluate strategies once tariffs are announced.
high · analyst_questionAlkem Laboratories Limited — Q1 FY26
Alkem Laboratories reported a strong Q1 FY26 with revenue of INR 3,371 crore (+11.2% YoY) and EBITDA of INR 739 crore (+21.4% YoY), driven by robust domestic growth (12% YoY) an...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Higher R&D and new business OpEx in H2
Management flagged that R&D spends (4.5-5% of sales) and OpEx from CDMO/medtech initiatives will weigh on H2 margins, potentially offsetting operational improvements.
medium · management_commentaryU.S. pricing erosion continues at 3-4%
U.S. business faces ongoing price erosion of 3-4% YoY, which could pressure margins if volume growth does not compensate.
medium · management_commentaryMedtech and CDMO businesses may take longer to break even
Medtech business expected to break even only by FY28, with losses of INR 40-60 crore in FY26-27; CDMO facility will start contributing meaningfully only from Q4.
medium · management_commentary